Literature DB >> 4042530

New insights into the pharmacokinetics of spironolactone.

H W Overdiek, W A Hermens, F W Merkus.   

Abstract

Four healthy men took a single oral dose of 200 mg spironolactone after a standardized breakfast. Blood samples were drawn until 24 hours after dosing. A specific HPLC method was used to determine the serum concentrations of spironolactone and its metabolites 7 alpha-thiomethylspirolactone, 6 beta-hydroxy-7 alpha-thiomethylspirolactone, and canrenone. Pharmacokinetic parameters were derived from the serum concentration-time course of each compound. Spironolactone, 7 alpha-thiomethylspirolactone, and canrenone are known to have antimineralocorticoid activity in man. Our study demonstrated that: (1) 7 alpha-Thiomethylspirolactone is the main metabolite of spironolactone after a single oral dose as judged by the AUC(0-24) and the maximum concentration; and (2) unchanged spironolactone was detected in serum, with a maximum concentration at 1 hour and detectable levels up to 8 hours after dosing. Our findings are contrary to the widely accepted belief that spironolactone is metabolized too rapidly to be detected in serum after oral dosing and that canrenone is the principal metabolite of spironolactone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042530     DOI: 10.1038/clpt.1985.206

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Interactions of aldosterone antagonist diuretics with human serum proteins.

Authors:  N Takamura; T Maruyama; S Ahmed; A Suenaga; M Otagiri
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

4.  Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.

Authors:  C S Cook; C L Hauswald; G L Schoenhard; C E Piper; A Patel; F M Radzialowski; J D Hribar; W Aksamit; P Finnegan; R H Bible
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

5.  Spironolactone and colitis: increased mortality in rodents and in humans.

Authors:  Laura A Johnson; Shail M Govani; Joel C Joyce; Akbar K Waljee; Brenda W Gillespie; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2011-11-13       Impact factor: 5.325

6.  Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia.

Authors:  I Terai; K Yamano; N Ichihara; J Arai; K Kobayashi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

Review 7.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  Improved bioavailability from a spironolactone beta-cyclodextrin complex.

Authors:  N T Yusuff; P York; H Chrystyn; P N Bramley; R D Swallow; B R Tuladhar; M S Losowsky
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction.

Authors:  Søren Ulrik Salling Sønder; Marianne Mikkelsen; Klaus Rieneck; Chris Juul Hedegaard; Klaus Bendtzen
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

10.  Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.

Authors:  Simon de Denus; Grégoire Leclair; Marie-Pierre Dubé; Isabelle St-Jean; Yassamin Feroz Zada; Essaïd Oussaïd; Martin Jutras; Michael M Givertz; Robert J Mentz; W H Wilson Tang; João Pedro Ferreira; Jean Rouleau; Javed Butler; Andreas P Kalogeropoulos
Journal:  Eur J Heart Fail       Date:  2020-04-01       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.